📰 For Grade News
Page 3 - For Grade News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from For Grade. Real-time updates on events, politics, business and more.
March 14, 2023
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the American Association for...
March 3, 2023
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for...
February 10, 2023
/PRNewswire/ -- GSK plc (LSE/NYSE: GSK) today reports that the US Food and Drug Administration (FDA) granted full approval for Jemperli (dostarlimab-gxly) for...
December 6, 2022
The benefit of adjuvant Verzenio in combination with endocrine therapy continues to deepen with additional follow-up, now demonstrating an absolut...
September 7, 2022
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib) and Retevmo® (selpercatinib) will be...
May 26, 2022
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the 2022 American Society of...
May 26, 2022
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the 2022 American Society of...
March 8, 2022
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from the pirtobrutinib and Verzenio® (abemaciclib) development programs will be...
October 21, 2021
Approval is based on positive results from the Phase 3 CheckMate -649 trial Opdivo plus chemotherapy is the first treatment regimen to demonstrate superior overall survival and progression-free survival compared to chemotherapy alone in this patient population Bristol Myers Squibb Receives European Commission Approval for Opdivo + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, ...
October 14, 2021
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the positive Phase 3 monarchE trial evaluating the investigational use of...